MedTrace Logo

Erythrocyte-Mediated Drug Delivery for the Prevention of Stent Restenosis

NCT00484965 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2007-06-12

No results posted yet for this study

Summary

The purpose of this study is to determine whether erythrocyte mediated dexamethasone delivery reduces circulating inflammatory markers after coronary stent implantation and improves clinical and angiographic outcomes.

Conditions

Interventions

PROCEDURE

Coronary stenting

Sponsors & Collaborators

  • University of Milan

    collaborator OTHER

  • University of Rome Tor Vergata

    lead OTHER

Principal Investigators

  • Francesco Versaci, MD, FACC · Tor Vergata University, Rome

  • Francesco Versaci, MD, FACC · Tor Vergata University, Rome

  • Luigi Chiariello, MD, FACC · Tor Vergata University, Rome

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Completion
2009-01-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00484965 on ClinicalTrials.gov